Literature DB >> 23084960

Costs of different follow-up strategies in early breast cancer: a review of the literature.

Marjan van Hezewijk1, M Elske van den Akker, Cornelis J H van de Velde, Astrid N Scholten, Elysée T M Hille.   

Abstract

We reviewed the literature between January 1985 and June 2011 on the costs of different follow-up strategies for patients treated for early breast cancer. A total of 186 abstracts were retrieved of which eleven publications were considered relevant; 6 randomised clinical trials, 4 retrospective cohort studies and 1 'minisymposium'. The follow-up strategies, outcome measures and methods of analysis used in these studies vary widely, so no general conclusions can be drawn. However, from the results we infer that patient-led follow-up by a nurse practitioner, follow-up by a general practitioner, or telephone follow-up is feasible and cost-effective, without routine additional tests, except annual mammograms. In this era of increasing health care costs, cost-effectiveness, evaluated in a standardised way, should be taken into account in future clinical trials.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23084960     DOI: 10.1016/j.breast.2012.09.009

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  8 in total

1.  Group medical consultations in the follow-up of breast cancer: a randomized feasibility study.

Authors:  Annemiek Visser; Hanneke W M van Laarhoven; Paulien H M Govaert; Margrethe S Schlooz; Lisette Jansen; Thijs van Dalen; Judith B Prins
Journal:  J Cancer Surviv       Date:  2015-01-13       Impact factor: 4.442

2.  Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial.

Authors:  Olivier Mir; Marie Ferrua; Aude Fourcade; Delphine Mathivon; Adeline Duflot-Boukobza; Sarah Dumont; Eric Baudin; Suzette Delaloge; David Malka; Laurence Albiges; Patricia Pautier; Caroline Robert; David Planchard; Stéphane de Botton; Florian Scotté; François Lemare; May Abbas; Marilène Guillet; Vanessa Puglisi; Mario Di Palma; Etienne Minvielle
Journal:  Nat Med       Date:  2022-04-25       Impact factor: 87.241

3.  Survivorship care and support following treatment for breast cancer: a multi-ethnic comparative qualitative study of women's experiences.

Authors:  Charlotte Tompkins; Karen Scanlon; Emma Scott; Emma Ream; Seeromanie Harding; Jo Armes
Journal:  BMC Health Serv Res       Date:  2016-08-18       Impact factor: 2.655

4.  Cost-Effectiveness of Intensive Vs. Standard Follow-Up Models for Patients with Breast Cancer in Shiraz, Iran

Authors:  Nahid Hatam; Niloofar Ahmadloo; Mina Vazirzadeh; Abdossaleh Jafari; Mehrdad Askarian
Journal:  Asian Pac J Cancer Prev       Date:  2016-12-01

5.  Cost-Consequence Analysis Alongside a Randomised Controlled Trial of Hospital Versus Telephone Follow-Up after Treatment for Endometrial Cancer.

Authors:  Padraig Dixon; Kinta Beaver; Susan Williamson; Chris Sutton; Pierre Martin-Hirsch; William Hollingworth
Journal:  Appl Health Econ Health Policy       Date:  2018-06       Impact factor: 2.561

6.  Systematic reviews as a "lens of evidence": Determinants of cost-effectiveness of breast cancer screening.

Authors:  Olena Mandrik; Obinna Ikechukwu Ekwunife; Filip Meheus; Johan L Hans Severens; Stefan Lhachimi; Carin A Uyl-de Groot; Raul Murillo
Journal:  Cancer Med       Date:  2019-09-30       Impact factor: 4.452

Review 7.  Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review.

Authors:  Isabella Sperduti; Patrizia Vici; Nicola Tinari; Teresa Gamucci; Michele De Tursi; Giada Cortese; Antonino Grassadonia; Stefano Iacobelli; Clara Natoli
Journal:  J Exp Clin Cancer Res       Date:  2013-11-11

8.  Knowledge structure and theme trends analysis on general practitioner research: A Co-word perspective.

Authors:  Yang Hong; Qiang Yao; Ying Yang; Jun-Jian Feng; Shu-de Wu; Wen-Xue Ji; Lan Yao; Zhi-Yong Liu
Journal:  BMC Fam Pract       Date:  2016-01-29       Impact factor: 2.497

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.